Literature DB >> 6800417

Characterization of the defect of the factor VIII/von Willebrand factor protein in von Willebrand's disease.

H R Gralnick, M C Cregger, S B Williams.   

Abstract

The factor VIII/von Willebrand factor (f.VIII/vWf) protein was purified from the plasma of a patient with von Willebrand's disease (vWd). The patient had all of the classic laboratory findings of vWd except for the ristocetin-induced platelet aggregation of his own platelet-rich plasma. The disease has been documented in three generations. Comparison of the purified normal and vWd f.VIIi/vWf protein revealed several abnormalities, including decreased concentration of f.VIII/vWf antigen; decreased specific vWf activity; absence of the larger molecular forms of the f.VIII/vWf protein; carbohydrate deficiencies affecting the sialic acid, penultimate galactose and N-acetylglucosamine moieties; and decreased binding of the f.VIII/vWf protein to its platelet receptor. These studies indicate the multiplicity of biochemical and functional abnormalities associated with the f.VIII/vWf protein in vWd. f.VIII/vWf protein to normal f.VIII/vWf protein that had been treated with 2-mercaptoethanol (2-ME) to reduce the multimer size and then treated with specific exoglycosidases to remove the sialic acid and penultimate galactose residues revealed similar biologic properties.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800417

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Vitreous, retinal and subretinal hemorrhages associated with von Willebrand's syndrome.

Authors:  T Shiono; S Abe; T Watabe; M Noro; M Tamai; Y Akutsu; M Ishikawa; S Suzuki; K Mori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

2.  von Willebrand's disease in identical twins.

Authors:  P Sivasankaran; H S Prasad; P Nalini
Journal:  Indian J Pediatr       Date:  1989 May-Jun       Impact factor: 1.967

3.  Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells.

Authors:  D C Lynch; R Williams; T S Zimmerman; E P Kirby; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

4.  The von Willebrand-syndrome.

Authors:  I Scharrer
Journal:  Blut       Date:  1983-09

5.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

6.  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.

Authors:  Lesley G Ellies; David Ditto; Gallia G Levy; Mark Wahrenbrock; David Ginsburg; Ajit Varki; Dzung T Le; Jamey D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-03       Impact factor: 11.205

7.  Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein.

Authors:  H R Gralnick; S B Williams; M E Rick
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

8.  Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.

Authors:  H R Grainick; S B Williams; L P McKeown; M E Rick; P Maisonneuve; C Jenneau; Y Sultan
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Glycogen storage disease type Ib: familial bleeding tendency.

Authors:  K Heyne; D Hosenfeld; W Grote; J Schaub
Journal:  Eur J Pediatr       Date:  1984-11       Impact factor: 3.183

10.  Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers.

Authors:  D D Wagner; T Mayadas; M Urban-Pickering; B H Lewis; V J Marder
Journal:  J Cell Biol       Date:  1985-07       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.